Background: The polymath entrepreneur Martine Rothblatt founded United Therapeutics (NASDAQ:UTHR) after her daughter contracted pulmonary arterial hypertension (PAH), a disease that is usually fatal. UTHR succeeded in bringing several drug products to treat PAH to FDA approval; each has the leading market share in its category, and the company has a multi-billion market capitalization. I am long large amounts of UTHR, and feel the bull case is strong despite meaningful headwinds. This stock may appeal both to growth investors as well as certain types of value investors.
Introduction: UTHR went public in the frenzied year of 1999. Going public in 1999 was a recipe for marked underperformance in the out years, and so it went for
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|